FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to new crystalline forms and salt forms of the TGF-βR1 inhibitor, as well as their use in the preparation of drugs for the treatment of cancer.
EFFECT: new crystalline forms of the compounds of formula (I), as well as compounds of formulas (II), (IV), (V), (VI), which have the properties of the TGF-βR1 inhibitor and can be used for the treatment of cancer mediated by inhibition of the TGF- βR1.
19 cl, 7 dwg, 5 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUND OF FGFR INHIBITOR IN SOLID FORM AND METHOD OF ITS PREPARATION | 2020 |
|
RU2810067C2 |
| SOLID FORM, CRYSTALLINE, AND CRYSTALLINE A OF FXR AGONIST AND METHOD FOR THEIR PRODUCTION AND THEIR APPLICATION | 2019 |
|
RU2804320C2 |
| CRYSTALLINE OR AMORPHOUS FORM OF FXR AGONISTS BEING STEROID DERIVATIVES, THEIR PRODUCTION METHOD AND THEIR USE | 2018 |
|
RU2800751C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
| SALTS AND CRYSTALLINE FORMS OF DIAZABENZOFLUORANTHENE COMPOUNDS | 2017 |
|
RU2762189C2 |
| SALT AND POLYMORPH OF A PHENYL-PYRIMIDONE COMPOUND, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 2018 |
|
RU2761213C2 |
| ALPHA- AND BETA-UNSATURATED AMIDE COMPOUND-A BENZOTRIAZOLE DERIVATIVE USED AS A TGF-ΒRI INHIBITOR | 2017 |
|
RU2737737C2 |
| LSD1 INHIBITOR SALT AND ITS POLYMORPHIC FORM | 2019 |
|
RU2794977C2 |
| STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | 2005 |
|
RU2330845C1 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
